Translational Research Office (TRO)


Funding Opportunities

There are a number of translational funding opportunities available to UCL and partner researchers internally and externally. The TRO helps PIs identify the most suitable scheme for their project.

These funds differ from standard project grants by being milestone driven with clear go/no go decision criteria which require active project management.

Internal (proof-of-concept) funding opportunities

  • UCL Therapeutic Acceleration Support (TAS) Fund - A list of previous TAS fund awarded projects can be found here
  • Biomedical Research Centre (BRC) Fund
  • EPSRC Impact Acceleration Award Funding
  • Internal Venture Funding (from the UCL Technology Fund and the Apollo Fund)
  • UCL Therapeutic Innovation Networks (TINs) pilot data funding schemes (more details on the TINs website)

Open Internal Opportunities

Small Molecules TIN Pilot Data Funding Scheme - Now OPEN

This is funding scheme for early career researchers, made available through the UCL/Wellcome Trust Translational Partnerships Award. For more information, visit the UCL Therapeutic Innovation Networks (TINs) website: https://www.ucl.ac.uk/therapeutic-innovation-networks/funding-opportunities

External funding opportunities

For more information about any translational funding schemes, to apply or to work out which scheme is best for you, please contact the Translational Research Group within the TRO. 

TRO funding opportunities

Previous opportunities:

Industrial Connectivity Awards - NOW CLOSED

UCL TRO invites members of the UCL community to apply for funding under the Proximity-to-Discovery award which was granted to the TRO from the MRC. The Industry Connectivity Awards are suitable for UCL researchers looking to promote their engagement with industry. 

Therapeutic Acceleration Support (TAS) Fund Call 7 - NOW CLOSED
  • Deadline for Applications: Friday 24th April 2020, 5pm 

The UCL Therapeutic Acceleration Support (TAS) Fund is supported by the MRC Confidence in Concept scheme, Wellcome Trust Institutional Strategic Support Fund and the three Biomedical Research Centres (BRC) affiliated with UCL (University College London Hospitals NHS Foundation Trust (UCLH) BRC, Great Ormond Street Hospital (GOSH) BRC and Moorfields BRC. 

It aims to accelerate the transition from discovery science to the early stages of therapeutic development by providing responsive and flexible funding to support preliminary translational work.

The scheme expects to typically fund individual projects in the range of £60-75K (directly incurred costs only) for up to 12 months.

Remit of this Call:

  • All modalities of therapy and diagnostics including engineering/medical technology and bioinformatics approaches can be submitted for consideration. Applications from across the breadth of diseases researched in UCL and its partner hospitals will be welcomed.
  • Applications with an industry partner are strongly encouraged.
  • Before applying please read the Application Brief to ensure that your project is in remit.  Applications that do not conform to the brief will not be considered for funding.

View the Application Form and Applicant Guidance document for further details

Enquiries about the scheme should be addressed to Dr Simon Eaglestone (simon.eaglestone@ucl.ac.uk) or Helen Cooksley (h.cooksley@ucl.ac.uk) in the Translational Research Office.


The Neurogenetic Therapies Programme - Now OPEN

The Neurogenetic Therapies Programme, funded by the Sigrid Rausing Trust, aims to accelerate the development and testing of novel genetics-based therapies for neurodegeneration and dementia. Preclinical and clinical projects will be supported in order to create a pipeline of new translational genetic therapies, from concept through to patients. Projects will be supported by both preclinical and clinical steering committees, as relevant. Therapeutic modalities may include, but not are limited to, viral delivered gene therapies, antisense oligonucleotide approaches. Novel approaches to delivery of neurogenetic therapies will also be considered. Partnerships with industry are welcome, as is co-funding from other sources.

The programme will provide awards between £10,000 to £250,000 to be used flexibly and against specific milestones.

Important dates:

  • Request For Proposals open: 23 March 2020
  • Proposals due: Midday 18 May 2020
  • Recipients announced: July 2020
  • Awards start: August 2020

For more information on selection criteria and requirements, please download the Request for Proposals PDF below: 

To apply, proposals must be submitted using the Neurogenetic Therapies Programme Expression of interest template attached below and emailed to a.kiely@ucl.ac.uk with the subject line Neurogenetics proposal [Name of applicant].